Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of May 20, 2026, LCTX trades at $1.31 with a market cap of $309.13M and a P/E ratio of -4.38. LCTX moved +8.75% today. Year to date, LCTX is -26.83%; over the trailing twelve months it is +141.25%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $6.25. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LCTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LCTX recently traded at $1.31. Market cap is $309.13M. P/E ratio is -4.38. Revenue is $14.78M.
| Metric | Value |
|---|---|
| Price | $1.31 |
| Market Cap | $309.13M |
| P/E Ratio | -4.38 |
| EPS | $-0.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.09 |
| 52-Week Low | $0.37 |
| Volume | 1.42M |
| Avg Volume | 0 |
| Revenue (TTM) | $14.78M |
| Net Income | $-64.01M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.56M | $-63.37M | $-0.28 |
| 2024 | $9.50M | $-18.58M | $-0.09 |
| 2023 | $8.95M | $-21.48M | $-0.12 |
| 2022 | $14.70M | $-26.35M | $-0.15 |
4 analysts cover LCTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.25.